TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05070312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: MEDI3506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: MEDI3506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05776615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: In the collection of Mobile Application group data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months.Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Questionnaire in the Neonatal Intensive Care Unit(NICU); System Availability Scale will be applied.
Study: NCT04741282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary telerehabilitation
Description: pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary telerehabilitation
Description: pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation training
Description: summarized Jacobson progressive muscle relaxation training method
Study: NCT04008576

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Blended Transdiagnostic treatment
Description: The treatment combines group face-to-face and Internet-delivered psychotherapy: 7 group sessions delivered every 3 weeks plus the use of an online treatment platform between sessions. Its goal is to learn and practice adaptive regulation strategies from a mechanistically transdiagnostic approach, with a focus on both negative and positive affectivity. Each group session will focus on one of the following core components: the first group session will focus on CBT traditional strategies such as motivation for change and psychoeducation about emotions; sessions 2 to 5 will focus on strategies to down-regulate negative affect: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, and interoceptive and situation-based emotion exposure; session 6 will focus on strategies to regulate positive affect; the final session will teach relapse prevention techniques. All the treatment components are delivered in 16 online treatment modules.
Study: NCT05454098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib with fed state
Description: 40 mg Clifutinib with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib with fasted state
Description: 40 mg Clifutinib without food
Study: NCT05504031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid coronary revascularization
Description: Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional revascularization
Description: Conventional revascularization with CABG of all significant stenoses through a sternotomy
Study: NCT05239156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Janesse
Description: Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Janesse
Description: Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Janesse
Description: Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan.
Study: NCT04938752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811-R
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811-R
Description: single dose administration (one tablet once a day)
Study: NCT05837325

Intervention type: PROCEDURE
Intervention: Oocyte Pick Up - Out of Study
Description: Aspiration of follicles. search for the oocyte(s) All oocytes are grouped in one dish.

Intervention type: PROCEDURE
Intervention: Denudation - Out of Study
Description: All oocytes are denuded together. Maturational stages are recorded.

Intervention type: PROCEDURE
Intervention: ICSI
Description: One oocyte injected at a time.

Intervention type: PROCEDURE
Intervention: ICSI
Description: One oocyte injected at a time.

Intervention type: PROCEDURE
Intervention: Culture
Description: One embryo per culture drop. Individual follow-up of the embryo development.

Intervention type: PROCEDURE
Intervention: Culture
Description: One embryo per culture drop. Individual follow-up of the embryo development.

Intervention type: GENETIC
Intervention: Biopsy
Description: One embryo per culture drop.

Intervention type: GENETIC
Intervention: Biopsy
Description: One embryo per culture drop.

Intervention type: PROCEDURE
Intervention: Vitrification
Description: One embryo per vitrification straw.

Intervention type: PROCEDURE
Intervention: Vitrification
Description: One embryo per vitrification straw.

Intervention type: PROCEDURE
Intervention: OPU - Study Group
Description: Measure the size of the follicle and aspirate only one follicle and flush. The needle before moving to the second ovary. Oocyte included in the study will be cultured separately (each ovary separately too).

Intervention type: PROCEDURE
Intervention: Denudation - Study Group
Description: Oocyte included in the study will be denuded separately. Maturational stages are recorded per follicle.
Study: NCT04396288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging at the forearm and at the tibia
Description: ultrasound imaging will be performed at the radius bone (forearm) and at the tibia, before, during, and after a change of intraosseous blood flow
Study: NCT06117033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video assisted mobilization training
Description: Preoperative video-assisted mobilization training was given to patients undergoing coronary artery bypass graft surgery
Study: NCT05986825

Intervention type: OTHER
Intervention: Verneuil questionnaire Validation
Description: Request patient to Complete the questionnaire for validation of the French version
Study: NCT06229483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION
Description: Tranexamic acid 20 mg/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, for the duration of surgery. Treatment is blinded.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline 20ml/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 ml/kg/hr infusion of 0.9 % sodium chloride for the duration of surgery. Treatment is blinded.
Study: NCT04863313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
Study: NCT05709314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX-2011P
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Study: NCT05304286

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
Study: NCT05731791

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy to partial breast
Description: Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy to partial breast
Description: Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).
Study: NCT06273826

Intervention type: DIAGNOSTIC_TEST
Intervention: Colorectal Leakage App
Description: The Colorectal Leakage App is a mobile application designed to aid in the early detection of anastomotic insufficiency after colorectal surgeries. The app is based on the Dutch Leakage Score (DLS) algorithm, which is a standardized protocol for postoperative monitoring.
Study: NCT06300671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot Posture Index-6
Description: Foot Posture Index 6 (API-6) is a clinical diagnostic tool that broadly measures whether a foot is in neutral, supination or pronation posture. During the evaluation, individuals' static standing postures in a comfortable position are observed and scored. When using API-6, researchers visually evaluate the foot according to 6 criteria, each rated on a 5-point (-2 to +2) Likert scale. Each item is scored between -2 (supination) and +2 (pronation) and 0 (for neutral position), with the total score being between -12 (high degree of supination) and +12 (high degree of pronation). The grouping of reference values showing foot posture can be summarized as follows; Neutral position from 0 to +5, pronation position from +6 to +9, hyperpronation position from +10 to +12, supination position from -1 to -5, and supination position from -6. It shows a high degree of supination position up to -12. Higher scores represent a more pronated foot posture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot Posture Index-6
Description: Foot Posture Index 6 (API-6) is a clinical diagnostic tool that broadly measures whether a foot is in neutral, supination or pronation posture. During the evaluation, individuals' static standing postures in a comfortable position are observed and scored. When using API-6, researchers visually evaluate the foot according to 6 criteria, each rated on a 5-point (-2 to +2) Likert scale. Each item is scored between -2 (supination) and +2 (pronation) and 0 (for neutral position), with the total score being between -12 (high degree of supination) and +12 (high degree of pronation). The grouping of reference values showing foot posture can be summarized as follows; Neutral position from 0 to +5, pronation position from +6 to +9, hyperpronation position from +10 to +12, supination position from -1 to -5, and supination position from -6. It shows a high degree of supination position up to -12. Higher scores represent a more pronated foot posture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot Posture Index-6
Description: Foot Posture Index 6 (API-6) is a clinical diagnostic tool that broadly measures whether a foot is in neutral, supination or pronation posture. During the evaluation, individuals' static standing postures in a comfortable position are observed and scored. When using API-6, researchers visually evaluate the foot according to 6 criteria, each rated on a 5-point (-2 to +2) Likert scale. Each item is scored between -2 (supination) and +2 (pronation) and 0 (for neutral position), with the total score being between -12 (high degree of supination) and +12 (high degree of pronation). The grouping of reference values showing foot posture can be summarized as follows; Neutral position from 0 to +5, pronation position from +6 to +9, hyperpronation position from +10 to +12, supination position from -1 to -5, and supination position from -6. It shows a high degree of supination position up to -12. Higher scores represent a more pronated foot posture.
Study: NCT06483139

Intervention type: PROCEDURE
Intervention: Plasma exchange
Description: Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy

Intervention type: DRUG
Intervention: Daratumumab
Description: Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
Study: NCT06387485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Anatomic Model
Description: Patient-specific 3D printed anatomic model for pre-surgical planning

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT/MRI
Description: Standard imaging type for bony tumors

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT/MRI
Description: Standard imaging type for bony tumors
Study: NCT05892939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal Oxytocin(24IU)
Description: Administration of intranasal Oxytocin(24IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal Placebo
Description: Administration of intranasal Placebo
Study: NCT05967052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin pharmacotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin pharmacotherapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Independent walking training
Description: Independent walking training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent walking training
Description: Independent walking training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent walking training
Description: Independent walking training
Study: NCT05491096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Training
Description: Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
Study: NCT05597540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short antibiotic treatment
Description: 7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual antibiotic treatment
Description: 14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
Study: NCT06502145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Level -1
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Level 0
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Level 1
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat Level -1
Description: 75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat Level -1
Description: 75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat Level 0
Description: 75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat Level 0
Description: 75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
Study: NCT05967052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent walking training
Description: Independent walking training

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06502145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat Level 1
Description: 100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat Level 1
Description: 100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
Study: NCT04698109

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study: NCT06396455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene block group
Description: The ISB group scanning was done by linear ultrasound probe just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle; the skin was disinfected, and the transducer was positioned in the transverse plane to identify the carotid artery. Once the artery was identified, the transducer was moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles. 3 ml lidocaine 1% was injected at puncture site The needle was then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction. After a careful aspiration, 20 ml of bupivacaine 0.25% was injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block group
Description: After cleaning the skin with an antiseptic solution, an ultrasound probe was put in sagittal orientation at the superior medial border of the scapula to identify the pleura and then moved laterally; when it was parallel to the spine of the scapula, the transducer was moved cephalad and the suprascapular fossa was identified, and then the transducer was moved lateral to locate the suprascapular notch. The suprascapular nerve was a round hyperechoic structure beneath the transverse scapular ligament in the scapular notch. 3 ml lidocaine 1% was injected at puncture site then the needle was inserted along the longitudinal axis of the ultrasound beam, and 10 ml of bupivacaine 0.25% was injected.